NCT05451329: A reported trial by VivaVision Biotech, Inc
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05451329 |
|---|---|
| Title | A Phase 2, Double-masked, Randomized, Vehicle-controlled, Dose-response Study Assessing the Safety and Ocular Hypotensive Efficacy of VVN539 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 12, 2022 |
| Completion date | Dec. 22, 2022 |
| Required reporting date | Dec. 22, 2023, midnight |
| Actual reporting date | Dec. 20, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |